Status:
COMPLETED
Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Non-valvular Atrial Fibrillation (NVAF)
Eligibility:
All Genders
20+ years
Brief Summary
In this study researchers want to learn more about on the safety of the drug Xarelto. The study will enroll patients for whom the treating doctor are prescribing Xarelto for the prevention of brain at...
Eligibility Criteria
Inclusion
- Female and male patients ≥ 20 years of age
- Diagnosis of non-valvular atrial fibrillation (NVAF)
- Patients for whom the decision to initiate treatment with rivaroxaban is made as per physician's routine treatment practice
- Previously documented CrCl of 15-50 mL/min within 6 months before enrollment (last available value)
Exclusion
- Contraindications for rivaroxaban according to the local market authorization/ Summary of Product Characteristics
- Patients participating in an investigational program with interventions outside of routine clinical practice.
- Planned treatment with other anticoagulants
- Expected renal-replacement therapy within the next 3 months
Key Trial Info
Start Date :
May 13 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 16 2023
Estimated Enrollment :
493 Patients enrolled
Trial Details
Trial ID
NCT04356989
Start Date
May 13 2020
End Date
January 16 2023
Last Update
December 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, Taiwan